新入荷 再入荷

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 7650円 (税込)
数量

商品詳細情報

管理番号 新品 :2110316765
中古 :2110316765-1
メーカー 259f6 発売日 2025-05-06 11:44 定価 9000円
カテゴリ

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its  Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate  Cancer CellsBardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells,Metabolic Reprogramming and Predominance of Solute Carrier Genes during  Acquired Enzalutamide Resistance in Prostate CancerMetabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer,Uncovering a Phenomenon of Active Hormone Transcriptional Regulation during  Early Somatic Embryogenesis in Medicago sativaUncovering a Phenomenon of Active Hormone Transcriptional Regulation during Early Somatic Embryogenesis in Medicago sativa,Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its  Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate  Cancer CellsBardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells,Metabolic Reprogramming and Predominance of Solute Carrier Genes during  Acquired Enzalutamide Resistance in Prostate CancerMetabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です